These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37775662)

  • 21. Hepatitis E Virus Capsid as a Carrier of Exogenous Antigens for the Development of Chimeric Virus-Like Particles.
    Lu T; Behloul N; Zhou Y; Baha S; Liu Z; Wei W; Shi RH; Meng J
    Intervirology; 2022; 65(1):37-48. PubMed ID: 34695827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanical tuning of virus-like particles.
    Radiom M; Keys T; Turgay Y; Ali A; Preet S; Chesnov S; Lutz-Bueno V; Slack E; Mezzenga R
    J Colloid Interface Sci; 2023 Mar; 634():963-971. PubMed ID: 36571858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Self-assembly of virus-like particles of rabbit hemorrhagic disease virus capsid protein expressed in Escherichia coli and their immunogenicity in rabbits.
    Guo H; Zhu J; Tan Y; Li C; Chen Z; Sun S; Liu G
    Antiviral Res; 2016 Jul; 131():85-91. PubMed ID: 27118636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice.
    Chen X; Zhang T; Liu H; Hao Y; Liao G; Xu X
    Hum Vaccin Immunother; 2018; 14(8):2025-2033. PubMed ID: 29683766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Leveraging Immunofocusing and Virus-like Particle Display to Enhance Antibody Responses to the Malaria Blood-Stage Invasion Complex Antigen PfCyRPA.
    Björnsson KH; Bassi MR; Knudsen AS; Aves KL; Morella Roig È; Sander AF; Barfod L
    Vaccines (Basel); 2024 Jul; 12(8):. PubMed ID: 39203985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chromatographically-purified capsid proteins of red-spotted grouper nervous necrosis virus expressed in Saccharomyces cerevisiae form virus-like particles.
    Choi YR; Kim HJ; Lee JY; Kang HA; Kim HJ
    Protein Expr Purif; 2013 Jun; 89(2):162-8. PubMed ID: 23537792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2.
    Smit MJ; Sander AF; Ariaans MBPA; Fougeroux C; Heinzel C; Fendel R; Esen M; Kremsner PG; Ter Heine R; Wertheim HF; Idorn M; Paludan SR; Underwood AP; Binderup A; Ramirez S; Bukh J; Soegaard M; Erdogan SM; Gustavsson T; Clemmensen S; Theander TG; Salanti A; Hamborg M; de Jongh WA; McCall MBB; Nielsen MA; Mordmüller BG;
    Lancet Microbe; 2023 Mar; 4(3):e140-e148. PubMed ID: 36681093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integrated molecular and bioprocess engineering for bacterially produced immunogenic modular virus-like particle vaccine displaying 18 kDa rotavirus antigen.
    Tekewe A; Fan Y; Tan E; Middelberg AP; Lua LH
    Biotechnol Bioeng; 2017 Feb; 114(2):397-406. PubMed ID: 27497268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Production and characterization of novel ssRNA bacteriophage virus-like particles from metagenomic sequencing data.
    Liekniņa I; Kalniņš G; Akopjana I; Bogans J; Šišovs M; Jansons J; Rūmnieks J; Tārs K
    J Nanobiotechnology; 2019 May; 17(1):61. PubMed ID: 31084612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Self-assembly of virus-like particles of canine parvovirus capsid protein expressed from Escherichia coli and application as virus-like particle vaccine.
    Xu J; Guo HC; Wei YQ; Dong H; Han SC; Ao D; Sun DH; Wang HM; Cao SZ; Sun SQ
    Appl Microbiol Biotechnol; 2014 Apr; 98(8):3529-38. PubMed ID: 24413974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Yeast-expressed bacteriophage-like particles for the packaging of nanomaterials.
    Freivalds J; Kotelovica S; Voronkova T; Ose V; Tars K; Kazaks A
    Mol Biotechnol; 2014 Feb; 56(2):102-10. PubMed ID: 23852987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Virus-like particle-display of the enterotoxigenic Escherichia coli heat-stable toxoid STh-A14T elicits neutralizing antibodies in mice.
    Govasli ML; Diaz Y; Puntervoll P
    Vaccine; 2019 Oct; 37(43):6405-6414. PubMed ID: 31515145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High immunogenicity of virus-like particles (VLPs) decorated with
    Yang JI; Sepúlveda D; Vardia I; Skov J; Goksøyr L; Sander AF; Lorenzen N
    Front Immunol; 2023; 14():1139206. PubMed ID: 37283749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Large-scale manufacture of VP2 VLP vaccine against porcine parvovirus in Escherichia coli with high-density fermentation.
    Wang J; Liu Y; Chen Y; Wang A; Wei Q; Liu D; Zhang G
    Appl Microbiol Biotechnol; 2020 May; 104(9):3847-3857. PubMed ID: 32130468
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vaccine synergy with virus-like particle and immune complex platforms for delivery of human papillomavirus L2 antigen.
    Diamos AG; Larios D; Brown L; Kilbourne J; Kim HS; Saxena D; Palmer KE; Mason HS
    Vaccine; 2019 Jan; 37(1):137-144. PubMed ID: 30459071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Engineering a Novel Modular Adenoviral mRNA Delivery Platform Based on Tag/Catcher Bioconjugation.
    Geng K; Rice-Boucher PJ; Kashentseva EA; Dmitriev IP; Lu ZH; Goedegebuure SP; Gillanders WE; Curiel DT
    Viruses; 2023 Nov; 15(11):. PubMed ID: 38005953
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of porcine circovirus type 2 (PCV2) capsid particle assembly and its application to virus-like particle vaccine development.
    Wu PC; Lin WL; Wu CM; Chi JN; Chien MS; Huang C
    Appl Microbiol Biotechnol; 2012 Sep; 95(6):1501-7. PubMed ID: 22526782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.
    Tumban E; Muttil P; Escobar CA; Peabody J; Wafula D; Peabody DS; Chackerian B
    Vaccine; 2015 Jun; 33(29):3346-53. PubMed ID: 26003490
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficient expression and purification of porcine circovirus type 2 virus-like particles in Escherichia coli.
    Wu PC; Chen TY; Chi JN; Chien MS; Huang C
    J Biotechnol; 2016 Feb; 220():78-85. PubMed ID: 26795354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a synthetic nanoparticle vaccine presenting the HIV-1 envelope glycoprotein.
    Ximba P; Chapman R; Meyers A; Margolin E; van Diepen MT; Sander AF; Woodward J; Moore PL; Williamson AL; Rybicki EP
    Nanotechnology; 2022 Sep; 33(48):. PubMed ID: 35882111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.